New obesity drug enters early human safety testing
NCT ID NCT07225556
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 4 times
Summary
This early-stage study is testing a new medicine called LY4167586 in people who are overweight or have obesity but are otherwise healthy. The main goal is to see if the drug is safe and how the body processes it after a single dose. About 84 participants will be randomly assigned to receive either the drug or a placebo, and the study lasts around 7 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704, United States
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?